You are on Trendlyne United States. Click here to go to India website or make United States as your default
person reading

About Avadel Pharmaceuticals plc - ADR - Company Information, Overview, History and Profile

What does Avadel Pharmaceuticals plc - ADR do?

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Avadel Pharmaceuticals plc - ADR Management structure

All Gross Remunerations are in USD
Mr. Richard J Kim
Chief Commercial Officer
-
2024
Gross Remuneration
Year
Mr. Thomas S. Mchugh
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Mr. Scott Macke
Vice President, Supply Chain and Operations
-
2024
Gross Remuneration
Year
Mr. Gregory J. Divis
Director and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. Jerad G. Seurer
General Counsel and Corporate Secretary
-
2024
Gross Remuneration
Year

Avadel Pharmaceuticals plc - ADR Board of directors

All Gross Remunerations are in USD
Dr. Naseem S Amin, M.D.
Independent Director
-
2024
Gross Remuneration
Year
Dr. Mark A. Mccamish, M.D.,PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. Eric J. Ende, M.B.A.,M.D.
Independent Director
-
2024
Gross Remuneration
Year
Mr. Geoffrey M. Glass
Non-Executive Chairman of the Board
-
2024
Gross Remuneration
Year
Mr. Gregory J. Divis
Director and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. Peter J. Thornton
Independent Director
-
2024
Gross Remuneration
Year